LEXEO Therapeutics announced a strategic investment from Sarepta Therapeutics to support the advancement of LEXEO’s adeno-associated virus gene therapy programs. In connection with this investment, the companies will explore the development of novel gene therapy candidates for a range of cardiovascular diseases. Financial details of the investment were not disclosed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRPT:
- Insiders Pour Millions Into These 2 Stocks, Analysts Say They Have up to 120% Upside — Here’s Why You Should Pay Attention
- Fly Insider: Applied Optoelectronics, Nucor among week’s notable insider trades
- Sarepta director buys $1.09M in common stock
- Take a Look at Sarepta’s (NASDAQ:SRPT) Latest Insider Trade
- Sarepta reports Q2 EPS (27c) , consensus ($1.78)